Is AME a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for AMETEK (AME) rests on Record orders tied to AI infrastructure, aerospace and defense: Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. The bear case rests on valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. Analysts covering it publish targets from $217.00 to $325.00 against a $234.84 share price on November 17, 2026, so even the professionals disagree by 38% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

AME key stats

At $234.84 on November 17, 2026, AMETEK (AME) has a market cap of $53.9B, a P/E of 33.1 on trailing earnings (24.4 on forward earnings) and a dividend yield of 0.58%. It next reports earnings around February 2, 2027 (estimated).

Market cap
$53.9B
P/E (trailing)
33.1
P/E (forward)
24.4
EPS (trailing 12 months)
$7.09
Price to book
4.6
Dividend yield
0.58%
Beta
0.97
Next earnings
around February 2, 2027 (estimated)

Market cap, P/E and yield are measured at the $234.84 price on November 17, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with AMETEK (AME)?

The last two weeks for AMETEK, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • AME closed at $234.84 on November 17, 2026, down 1.5% over the past five trading days (from $238.31).
  • AMETEK next reports quarterly results around February 2, 2027 (estimated).
  • On November 6, 2026, AMETEK filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
  • On November 3, 2026, AMETEK filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 3, 2026, AMETEK filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 4, 2026, Citigroup raised its target to $270.00 from $263.00 (Neutral).
  • On November 4, 2026, RBC Capital raised its target to $308.00 from $291.00 (Outperform).
  • On November 4, 2026, Mizuho lowered its target to $275.00 from $285.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume. The business model is as much capital allocation as manufacturing. AMETEK has bought hundreds of businesses over decades, layering them onto a decentralized operating system and pulling margins up through its internal operational excellence program. That shows in the numbers: operating margin near 26 percent, profit margin around 20 percent, and trailing free cash flow of roughly $1.5 billion (operating cash flow near $2.0 billion) on about $7.9 billion of trailing revenue. Q2 2026 was a record quarter, with sales up about 15 percent to roughly $2.04 billion, adjusted EPS of about $2.09 against a ~$1.99 consensus, orders up about 28 percent to a record $2.3 billion and backlog near $4.11 billion. Management raised 2026 adjusted EPS guidance to roughly $8.20 to $8.30, and analysts now average about $8.38. A $5 billion purchase of Indicor's instrumentation portfolio is expected to close in the second half. The counterweight is valuation: at $248.41 per share on October 16, 2026 and a market cap near $57 billion, the stock trades near the top of its historical range, up about 18.8 percent year to date and 34.6 percent over one year.

The bull case: what would have to be true for $325.00

The most optimistic published target on AME is $325.00, +38.4% from the $234.84 share price on November 17, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Record orders tied to AI infrastructure, aerospace and defense

Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. Demand broadened across AI data center infrastructure (power quality, thermal management and interconnect content), commercial aerospace, defense and medical technology. A backlog of that size gives revenue visibility well into 2027 and is the main reason management lifted second-half organic growth expectations. Consensus for Q3 2026 calls for revenue of about $2.13 billion and EPS of about $2.11.

2. The $5 billion Indicor instrumentation acquisition

AMETEK agreed to buy Indicor's instrumentation portfolio for about $5 billion, the largest deal in its history, with closing targeted for the second half of 2026. Management has pointed to 10 to 12 percent cost synergies. The deal extends the EIG franchise and tests whether the acquisition playbook that built the company still works at a materially larger check size. Analysts' 2027 revenue estimate of about $9.9 billion, versus about $8.45 billion for 2026, reflects the expected contribution.

3. Paragon Medical and the EMG margin story

The Electromechanical Group posted roughly 15 percent organic sales growth in Q2 2026 with about 290 basis points of core margin expansion, led by Paragon Medical. Medical contract manufacturing adds a recurring, regulated revenue stream with switching costs. Continued margin recovery at Paragon is one of the clearer internal levers on group profitability.

4. Cash generation funding the next deal

Trailing free cash flow of roughly $1.5 billion against about $2.31 billion of total debt and around $495 million of cash leaves AMETEK with substantial capacity to keep acquiring, though the Indicor purchase will use much of it. The dividend is deliberately small (roughly a 0.55 percent yield at about a 19 percent payout), because retained cash is redeployed into M&A. The compounding case rests on that reinvestment continuing to earn returns above cost of capital.

The bear case: what would have to be true for $217.00

The most pessimistic published target is $217.00, -7.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks AMETEK is worth if the risks below bite instead of the drivers above.

Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. The Indicor deal carries integration and leverage risk at a size AMETEK has not attempted before, and cost synergies of 10 to 12 percent are a target rather than a result. Roughly half of sales come from outside the United States, exposing results to currency, tariffs and global capital spending cycles, while short-cycle instrument orders can turn quickly if industrial demand cools. AI infrastructure and defense are currently strong contributors and would become concentration risks if either budget cycle reversed. Expectations into the November 3, 2026 report are elevated after four consecutive EPS beats and target increases from Morgan Stanley (to $275) and Citigroup (to $263) in October. Separately, AMETEK carries long-running environmental and toxic tort litigation related to groundwater contamination from a former subsidiary site in El Cajon, California, an ordinary-course legal exposure disclosed in its filings; no active securities-fraud class action was identified against the company as of August 2026.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AME already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on AME

18 analysts cover AME, with an average target of $287.44 (+22.4% against $234.84) and a split of 14 buy, 6 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the AME forecast and price target page.

How is AME valued?

Market cap, P/E and dividend yield at today's price are in the AME key stats above. The business figures below come from AMETEK's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$7.86B; Q2 2026 up ~15% YoY
  • Operating margin: ~26%
  • Net income (TTM): ~$1.58B (~20% margin)
  • Q2 2026 sales / adj. EPS: ~$2.04B (+15%) / ~$2.09 vs ~$1.99 est.

As of October 2026: As of October 16, 2026, AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 36, a forward P/E near 26 and EV/EBITDA around 23.5. The premium reflects roughly 26 percent operating margins, steady free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares closed at $248.41 against a 52-week range of roughly $183 to $261 and an average analyst target near $282, with Q3 2026 results due November 3.

How do you decide if AME is a buy?

Whether AME is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold AME indirectly through an index or sector ETF before adding more.

What would change your mind on AME

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Record orders tied to AI infrastructure, aerospace and defense stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the AME stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AME against your real portfolio and see your actual exposure before deciding.

Your questions about AMETEK

Ask Walnut's AI anything about AME and see how it fits what you own.

FAQ

Is AME a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Record orders tied to AI infrastructure, aerospace and defense, with revenue (ttm) at ~$7.86B; Q2 2026 up ~15% YoY. The bear case rests on valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. Analysts covering it are spread from $217.00 to $325.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell AME?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $217.00, -7.6% from the $234.84 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for AME?

+

Record orders tied to AI infrastructure, aerospace and defense. Q2 2026 orders rose about 28 percent to a record $2.3 billion, lifting backlog to roughly $4.11 billion. The most optimistic analyst target on AME is $325.00, +38.4% from the $234.84 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for AME?

+

Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. The Indicor deal carries integration and leverage risk at a size AMETEK has not attempted before, and cost synergies of 10 to 12 percent are a target rather than a result. Roughly half of sales come from outside the United States, exposing results to currency, tariffs and global capital spending cycles, while short-cycle instrument orders can turn quickly if industrial demand cools. AI infrastructure and defense are currently strong contributors and would become concentration risks if either budget cycle reversed. Expectations into the November 3, 2026 report are elevated after four consecutive EPS beats and target increases from Morgan Stanley (to $275) and Citigroup (to $263) in October. Separately, AMETEK carries long-running environmental and toxic tort litigation related to groundwater contamination from a former subsidiary site in El Cajon, California, an ordinary-course legal exposure disclosed in its filings; no active securities-fraud class action was identified against the company as of August 2026. The most pessimistic published target is $217.00, -7.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does AMETEK do?

+

AMETEK is a Pennsylvania-based serial acquirer that makes niche electronic instruments and electromechanical devices for aerospace, defense, medical and process markets.

What would have to change for AME to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Record orders tied to AI infrastructure, aerospace and defense) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does AMETEK actually make?

+

AMETEK makes electronic instruments and electromechanical devices. The Electronic Instruments Group builds analytical, test, process and aerospace instrumentation such as power quality monitors and materials analysis systems. The Electromechanical Group makes engineered connectors, precision motion components, thermal management products and medical device components through Paragon Medical.

Is AME a good long term compounder?

+

AMETEK is commonly grouped with Roper, Fortive and Danaher as a serial-acquirer compounder. It has bought hundreds of niche businesses over decades and lifted their margins, producing roughly 26 percent operating margins and about $1.5 billion of trailing free cash flow. Whether that record continues at larger deal sizes is the open question.

How did AMETEK do in Q2 2026?

+

It was a record quarter. Sales rose about 15 percent to roughly $2.04 billion, adjusted EPS was about $2.09 (up roughly 17 percent and ahead of the ~$1.99 estimate), orders climbed about 28 percent to a record $2.3 billion and backlog reached about $4.11 billion. Management raised full-year adjusted EPS guidance to roughly $8.20 to $8.30.

Walnut is informational, not investment advice, and gives no verdict on AME. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 17, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks